Literature DB >> 19911701

TP53 codon 72 polymorphism and breast cancer in northern Iran.

Masood Kazemi1, Zivar Salehi, Roohi Jamal Chakosari.   

Abstract

The p53 gene is one of the most extensively studied human genes because of its role as a tumor suppressor gene. Its diverse functions include DNA binding, cell cycle control, DNA repair, differentiation, genomic plasticity, and apoptosis. A common polymorphism of the p53 gene at codon 72 has been associated with human cancer susceptibility and prognosis. In this study, we investigated p53 codon 72 polymorphism in 42 breast cancer cases and 60 healthy individual in northern Iran. Genomic DNA was extracted from fresh tumor tissues of patients and blood samples of healthy individuals. AS-PCR method was applied for determination of codon 72 polymorphism. The distribution of genotypes in breast cancer cases and controls were different (p = 0.001). Pro allele was significantly associated with the presence of breast cancer (odds ratio = 1.5 and 95% confidence interval = 0.85-2.63). Pro/Pro genotype was overrepresented in breast cancer. Based on these data, it is suggested that Pro allele may modify the risk of breast cancer in northern Iranian women.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19911701     DOI: 10.3727/096504009789745629

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  9 in total

1.  Association of p53 codon 72 genetic polymorphism with the risk of ulcerative colitis in northern Iran.

Authors:  Salaheddin Vaji; Zivar Salehi; Keyvan Aminian
Journal:  Int J Colorectal Dis       Date:  2010-07-29       Impact factor: 2.571

2.  Association of the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis.

Authors:  Meire Luzia Gonçalves; Sarah Moreira Borja; Jacqueline Andréia Bernardes Leão Cordeiro; Vera Aparecida Saddi; Flávio Monteiro Ayres; Cesar Augusto Sam Tiago Vilanova-Costa; Antonio Márcio Teodoro Cordeiro Silva
Journal:  Springerplus       Date:  2014-12-17

3.  The Evaluation of p53 Polymorphism at Codon 72 and Association With Breast Cancer in Iran: A Systematic Review and Meta-analysis.

Authors:  Abozar Soleimani; Yousef Rahmani; Negin Farshchian; Ali Delpisheh; Kivan Khassi; Afshar Shahmohammadi; Nasrin Amirifard
Journal:  J Cancer Prev       Date:  2016-12-30

Review 4.  Association of p53 codon 72 Arg>Pro polymorphism and risk of cancer in Iranian population: A systematic review and meta-analysis.

Authors:  Daem Roshani; Alina Abdolahi; Shima Rahmati
Journal:  Med J Islam Repub Iran       Date:  2017-12-27

5.  The Dilemma of TP53 Codon 72 Polymorphism (rs1042522) and Breast Cancer Risk: A Case-Control Study and Meta-Analysis in The Iranian Population.

Authors:  Fahimeh Afzaljavan; Negin Chaeichi Tehrani; Mahdi Rivandi; Saeed Zarif Ghasemian; Elham Vahednia; Reza Khayami; Mohammad Abavisani; Alireza Pasdar
Journal:  Cell J       Date:  2019-10-14       Impact factor: 2.479

6.  p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies.

Authors:  Brehima Diakite; Yaya Kassogue; Guimogo Dolo; Jun Wang; Erin Neuschler; Oumar Kassogue; Mamadou L Keita; Cheick B Traore; Bakarou Kamate; Etienne Dembele; Sellama Nadifi; Robert L Murphy; Seydou Doumbia; Lifang Hou; Mamoudou Maiga
Journal:  BMC Med Genet       Date:  2020-10-19       Impact factor: 2.103

7.  p53 codon 72 polymorphism and breast cancer risk: A meta-analysis.

Authors:  Jing Hou; Yuan Jiang; Wenru Tang; Shuting Jia
Journal:  Exp Ther Med       Date:  2013-03-20       Impact factor: 2.447

8.  Joint detection of multiple immunohistochemical indices and clinical significance in breast cancer.

Authors:  En-Qi Qiao; Minghua Ji; Jianzhong Wu; Jian Li; Xinyu Xu; Rong Ma; Xiaohua Zhang; Yuejun He; Quanbin Zha; Xue Song; Liwei Zhu; Ji-Hai Tang
Journal:  Mol Clin Oncol       Date:  2013-05-08

9.  Relationship between p53 gene codon-72 polymorphisms and hypertrophic scar formation following caesarean section.

Authors:  Jianhua Gao; Ying Chen; Nong Liao; Wei Zhao; Weisen Zeng; Yingtao Li; Shaojing Wang; Feng Lu
Journal:  Exp Ther Med       Date:  2014-03-05       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.